Compagnie Lombard Odier SCmA’s Novavax NVAX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-300	Closed	-$1K	–	655
2021 Q4	$1K	Buy	+300	New	+$51.5K	﹤0.01%	677

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Compagnie Lombard Odier SCmA's NVAX Position: Q3 2024 in Review

Compagnie Lombard Odier SCmA sold out of Novavax (NVAX) in Q3 2024, closing a stake of 850 shares — an estimated $10.8K sold.

Compagnie Lombard Odier SCmA first reported a position in NVAX in Q2 2016 and held it in 16 quarters. The position peaked at $12.1M in Q1 2021. 238 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

Compagnie Lombard Odier SCmA reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 850 Novavax shares in Q3 2024, an estimated $10.8K.
Compagnie Lombard Odier SCmA first reported a position in Novavax in Q2 2016 and held it in 16 quarters.
Compagnie Lombard Odier SCmA's Novavax position peaked at $12.1M in Q1 2021.
238 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2024, filed 11 Oct 2024.